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Abstract
Purpose—Cognitive functioning impacts health-related quality of life (HRQOL) for individuals 
with Huntington disease (HD). The Neuro-QoL includes two patient-reported outcome (PRO) 
measures of cognition - Executive Function (EF) and General Concerns (GC). These measures 
have not previously been validated for use in HD. The purpose of this analysis is to evaluate the 
reliability and validity of the Neuro-QoL Cognitive Function measures for use in HD.
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Methods—Five-hundred-ten individuals with prodromal or manifest HD completed the Neuro-
Qol Cognition measures, two other PRO measures of HRQOL (WHODAS 2.0 and EQ5D), and a 
depression measure (PROMIS Depression). Measures of functioning (the Total Functional 
Capacity [TFC] and behavior (Problem Behaviors Assessment) were completed by clinician 
interview. Objective measures of cognition were obtained using clinician-administered Symbol 
Digit Modalities Test (SDMT) and the Stroop Test (Word, Color, and Interference). Self-rated, 
clinician-rated, and objective composite scores were developed. We examined the Neuro-Qol 
measures for reliability, convergent validity, discriminant validity, and known-groups validity.
Results—Excellent reliabilities (Chronbach’s alphas ≥ 0.94) were found. Convergent validity 
was supported, with strong relationships between self-reported measures of cognition. 
Discriminant validity was supported by less robust correlations between self-reported cognition 
and other constructs. Prodromal participants reported fewer cognitive problems than manifest 
groups, and early-stage HD participants reported fewer problems than late-stage HD participants.
Conclusions—The Neuro-QoL Cognition measures provide reliable and valid assessments of 
self-reported cognitive functioning for individuals with HD. Findings support the utility of these 
measures for assessing self-reported cognition.
Keywords
Huntington disease; Cognition; Neuro-QoL; Patient-centered outcomes
Huntington disease (HD) is a hereditary neurodegenerative disorder caused by a CAG triplet 
repeat expansion in the gene huntingtin. [1–4] Average prevalence rates for HD in North 
America are estimated to be 7.33 per 100,000 individuals. [5] Individuals with the HD gene 
expansion typically exhibit cognitive difficulties, which are both insidious and progressive. 
[6] Cognitive function is associated with health-related quality of life (HRQOL) for persons 
with HD. [7] HRQOL is a multidimensional construct reflecting the impact that a disease or 
disability has on mental, physical and social well-being. [8] Although there is no cure for 
HD, early identification and characterization of cognitive problems may help clinicians 
provide strategies to patients and their families to adapt their daily activities to improve 
function. [9; 10]
Investigators and clinicians commonly use standardized clinician-administered cognitive 
tests to monitor the cognitive status of patients with HD. For example, the Unified 
Huntington Disease Rating Scale (UHDRS) [11] includes objective tests with demonstrated 
sensitivity to early cognitive changes, [12] including the Symbol Digit Modalities Test, [13] 
the Stroop Interference Test, [14; 15] and the Verbal Fluency Test. [16] While 
neuropsychological tests provide precise measures of how a patient functions cognitively 
within a controlled environment, they provide more limited information about how an 
individual functions in day-to-day life, given the demands of the natural environment. [17–
20] An alternative approach is to use self-reported cognition. Yet research in other clinical 
populations (e.g., cancer) suggests that patient perception of their own cognitive function, 
rather than their cognitive performance per se, is more relevant to HRQOL. [21] Monitoring 
perceived cognition using psychometrically-sound and clinically valid PRO measures is 
Lai et al. Page 2
Qual Life Res. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
important because cognitive complaints have a direct impact upon HRQOL. No disease-
specific PRO measure is currently available for individuals with HD.
The Neuro-QoL [22; 23] was initiated by the National Institute of Neurological Disorders 
and Stroke (NINDS) to develop a HRQOL measurement system for people with 
neurological conditions. It was developed by gathering input from individuals with 
neurological conditions and experts, and establishing its psychometric properties using both 
classical and modern item response theory (IRT) approaches. [22; 24–27] The Neuro-QOL 
has not previously been validated in individuals with HD. Such a measurement tool may 
provide a viable assessment of self-reported cognition for this population, but reliability and 
validity data are needed to support this premise. To meet this need, this study aimed to 
establish the reliability and validity of the Neuro-QoL Cognitive Function measures in 
individuals with HD by comparing scores obtained from the Neuro-QoL Cognitive Function 
measures to those obtained from objective measures via clinician-administered 
neuropsychological tests, clinician-rated cognition, and self-reported cognition via validated 
questionnaires. This study also examined convergent validity, discriminant validity, and 
known-groups validity of the Neuro-QoL Cognitive Function measures using clinical 
information. As cognitive impairment was suspected as being a result of depression, [28] we 
evaluated the association of the Neuro-QoL Cognitive Function measures with depressive 
symptoms. We hypothesized that self-reported cognition tapped domains of both cognition 
and depression and thus would be correlated with objective and clinician-rated cognition as 
well as with depression (though with smaller magnitudes of the latter).
METHODS
Sample
This analysis uses data from 510 individuals with prodromal or manifest HD who 
participated in the HDQLIFE study. For a full description of the study, see Carlozzi, 
Schilling, Lai, et al., 2016. [29] Participants need to be at least 18 years old, able to read and 
understand English, and must have a positive test for the HD gene mutation but no clinical 
diagnosis based on their neurological exam (prodromal) and/or a clinical diagnosis of HD 
(made by a neurologist; manifest HD). The Total Functional Capacity (TFC) scale from the 
UHDRS, [30] a 5-item clinician-rated measure (score range: 0–13) with established reliably 
measuring functional decline with HD disease progression, [31; 32] was used to classify 
participants with a manifest HD diagnosis as either early-stage (scores: 7–13) or later-stage 
(scores: 0–6).
Participants were recruited from eight specialized treatment centers across the nation, the 
National Research Roster for Huntington’s disease, existing online medical record data 
capture systems, [33] and articles/advertisements in HD-specific newsletters and websites, 
as well as through the Predict-HD research study. [34] Of the 510 participants, 198 had 
prodromal HD (CAG > 35, but no HD clinical diagnosis based on the UHDRS motor score), 
195 had early-stage HD (sum scores of 7–13 on the TFC), and 117 had later-stage HD (sum 
scores of 0–6 on the TFC). Table 1 shows demographic information. Participants ranged in 
age from 18–81 years (M = 49.1, SD = 13.3), 40.8% of participants were male, and most 
were Caucasian (96.1%). Significant differences were seen for age, which was expected, F 
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(2, 507) = 46.466, p< .0001, since people in the prodromal stage of HD are typically 
younger than people in the early-stage and the late-stage HD groups. Additionally, the early-
stage HD group was younger than the late HD group. Participants’ education ranged from 4 
to 26 years (M = 15.1, SD = 2.9). While there were group differences in education, F (2, 
505) = 15.756, p< .0001, these differences were small; early- (M = 14.7, SD = 2.8) and late-
stage HD (M = 14.2, SD = 2.6) had 1 to 1.5 years less education relative to the prodromal 
HD group (M = 15.9 years, SD = 2.9).
This project was approved by the Institutional Research Board of all participating 
institutions. All participants provided informed consent prior to participation.
Measures
Emotional Functioning Measures—Participants completed PROMIS Depression, [35–
38] a self-report measure assessing sadness and hopelessness, using computerized adaptive 
testing (CAT). This measure is scored on a T-metric (with a mean of 50 and standard 
deviation of 10); the referent population is the general U.S. population. Higher scores 
indicate increased depression severity.
A single item from the Problem Behaviors Assessment (PBA-s) [39] was used to represent 
clinician-rated depression. The PBA-s is a clinician-administered semi-structured interview 
assessment of behavior that includes 11 items that assess depression, suicidal ideation, 
anxiety, irritability, aggression, apathy, obsessive-compulsive behaviors, perseverative 
thinking, paranoid thinking/delusions, hallucinations and disorientation. Each item is rated 
for both severity and frequency on a 5-point scale. We used the clinician-rated assessment of 
depression in this study.
Cognitive Measures
Self-reported Cognition: Participants completed Neuro-QoL Applied Cognition – General 
Concerns (GC) and Neuro-QoL Executive Function (EF) item banks, which have also been 
validated in samples of persons with neurological conditions, although not previously in HD. 
[22] Items included in the GC and EF are listed in the Appendix. The 18-item GC measures 
perceived difficulties in everyday cognitive abilities such as memory, attention, and decision 
making, while the 13-item EF emphasizes difficulties in applications of mental function 
related to planning, organizing, calculating, and working with memory and learning. Both 
GC and EF were administered as computerized adaptive tests (CATs) and static short forms 
online. The Neuro-QoL scores were reported using a T-score scoring system, in which the 
general neurological population mean=50 and standard deviation=10. Higher scores 
represent better cognitive function. The unidimensionality of these measures have previously 
been established. [22]
The WHODAS 2.0 [40] consists of 12 items assessing generic function-related HRQOL 
including: understanding and communication, self-care, mobility, interpersonal relations, 
work and household roles, and community and civic roles. The WHODAS 2.0 has been 
validated in an HD sample. [41] Items are rated on a scale of 0 to 4; higher scores indicate 
poorer health.
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Clinician-administered Neurocognitive Tests: A certified cognitive examiner at each site 
administered the Symbol Digit Modalities Test (SMDT), [13] and the Stroop Test, [42] both 
of which have previously been associated with functional decline in prodromal and 
diagnosed HD. [43] The Symbol Digit Modalities Test [SMDT] [13] is a psychomotor 
measure that examines processing speed. This written test requires the participant to 
associate numbers and symbols using a key. The score reflects the number of items 
completed correctly in 90 seconds. Age and education corrected standardized scores (M 
=100; SD = 15) were used in analyses. Higher scores indicate better cognitive functioning. 
The Stroop Test [42] provides a measure of executive function including cognitive flexibility 
and resistance to interference (i.e., the ability to inhibit over-learned verbal responses), and 
consists of three components: Stroop Word, Stroop Color, and Stroop Interference. Scores 
reflect number correct in 45 seconds; higher scores indicate better performance.
Clinician-rated Cognition: As mentioned above, the (PBA-s) [39] is a clinician-
administered semi-structured interview assessment of behavior. In this study, Perseverative 
Thinking and PBA-s Disoriented Behavior severity scores were used with both of these 
severity scores reversed so that higher scores indicating better cognitive function (i.e., less 
perseverative thinking and disoriented behavior, respectively).
Composition scores: Composite scores for each type of cognition measure 
(neuropsychological test, clinician-rated, and self-reported) described above were generated 
to examine convergent and discriminant validity between the Neuro-QoL and other 
cognition measures that were validated in HD. The self-rated composite score was created 
using the two self-reported cognition items from the WHODAS44: “In the last 30 days, how 
much difficulty did you have in: 1) Learning a new task, for example, learning how to get to 
a new place?” and 2) Concentrating on doing something for ten minutes?”. The objective 
composite was created using scores from the SMDT and Stroop Test (Word, Color and 
Interference). The clinician-rated composite was created using Perseverative Thinking and 
PBA-s Disoriented Behavior severity scores. All composite scores were created by reverse 
scoring the items when needed (i.e., higher scores representing better cognition), 
transforming scores for each measure to z-scores, taking the average of the scores, and 
transforming the score to a T-score with mean of 50 and SD of 10.
Analyses
Cronbach’s alphas were calculated to evaluate the reliability (internal consistency) of the 
Neuro-QOL Cognitive function measures (criterion: ≥ 0.70 [44; 45]). Floor and ceiling 
effects were used to describe whether the Neuro-QoL GC and EF sufficiently covered 
individuals’ perception of their cognition (criterion: proportion of participants with the 
lowest or the highest possible scores ≤ 20% [46; 47]). Correlation coefficients were used to 
evaluate the relationships between the Neuro-QoL GC and EF versus the three composite 
cognition scores. We defined convergent validity as high correlations (≥ 0.6) between the 
Neuro-QoL GC and EF and the self-reported composite previously described. [48] 
Discriminant validity would be supported by correlations that were lower in magnitude than 
those among the convergent validity correlations (by greater than or equal to 0.1 points). 
[48] Correlations were also calculated to examine the relationship between Neuro-QoL GC 
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and EF and depressive symptoms reported by individuals with HD and clinicians, in which a 
small to moderate relationship was expected. We also calculated correlations controlling for 
depression due to the potential impact of depression on cognitive function.
Analysis of variance (ANOVA) was used to evaluate whether Neuro-QoL GC and EF could 
significantly differentiate individuals with different stages within the disease (i.e., 
prodromal, early- or late-stage HD) to evaluate the known-groups validity. Partial eta 
squared, η2, was estimated to determine the strength of EF and GC being a predictor of 
staging groups. Partial eta squared (η2) is defined as variance explained by X/(explained 
variance by X + total unexplained variance of Y). Any variation explained by other 
independent variables is removed from the denominator. This allows a researcher to compare 
the effect of the same variable across different studies, which contain different covariates or 
other factors. η2 is considered small when its value is between 0.01 (inclusive) and 0.06, 
medium when between 0.06 (inclusive) and 0.14, and large when η2 ≥ 0.14. [49; 50]
Criterion validity was examined using a receiver operating characteristic (ROC) analysis by 
comparing diagnostic performance of Neuro-QoL GC and EF between individuals with 
prodromal vs. manifest HD. The area under the curve (AUC) values, a measure of 
discriminatory ability of the test to correctly identify prodromal vs. manifest HD, are 
interpreted as ≥ 0.9 as excellent, ≥ 0.8 as good, ≥ 0.7 as fair, and < 0.7 as poor. [51] We used 
a logistic regression model to evaluate how well EF and GC discriminated between 
prodromal versus manifest HD as well as between participants with and without clinically 
impaired cognition (defined as ≥ 1 SD below the normative mean on the SDMT). This was 
conducted to determine whether individuals with HD were at greater risk for cognitive 
function difficulties than the general population. According to the normal curve, 16% of the 
scores are expected to fall 1 SD below the mean (i.e., impaired); therefore, impairment rates 
that exceed 16% indicate greater impairment than would be expected compared to 
demographically-comparable neurologically healthy peers. [52] Likelihood ratios (i.e., 
sensitivity/[1-sensitivity]) of ≥ 2 indicated a minimum standard for differentiating between 
HD groups. [53] We considered validity and reliability were supported if 75% of the results 
are in accordance with the hypotheses. [54]
RESULTS
Table 2 provides descriptive data and reliability data for the Neuro-QoL Cognitive Function 
measures. Average times for individuals to complete measures were between 40 and 69 
seconds. Cronbach’s Alpha exceeded a priori criterion for both Neuro-QoL Cognitive 
Function measures. Less than 5% (range: 0.8%–1.7%) of participants reported the lowest 
possible scores (ceiling effect; low functioning) while about 7.2% (GC via CAT) to 18.5% 
(EF via SF) reported highest possible scores (floor effect; high function). Though floor and 
ceiling rates met our priori criteria, CAT captured EF and GC better than SFs given its 
smaller ceiling and floor effects. The EF CAT scores showed that floor effects decreased 
along with disease severity, with 21.5%, 6.3% and 0% for prodromal, early- and late-stage 
HD, respectively. For GC CAT scores, floor effects were 9.8%, 5.2% and 5.1% for 
prodromal, early- and late-stage HD, respectively. Results from CAT administration were 
used for further analyses.
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Table 3 shows the correlation matrix of EF, GC, the objective cognition composite, the self-
rated cognition composite, the clinician-rated cognition composite, and PROMIS 
Depression. When data from all participants were analyzed together (Table 3a), correlations 
ranged from 0.342 (GC versus clinician-rated composite) to 0.739 (EF versus GC). The 
pattern of correlations supported convergent and discriminant validity. Consistent with 
proposed hypotheses, EF and GC had high correlations with one another and with the self-
rated composite, and lower correlations with the clinician-rated measures (by ≥ .10). The 
highest correlations were among self-report measures, and lower correlations were found 
among self-rated and objective composites. Correlations for EF ranged from r = 0.41 
(PROMIS Depression) to r = 0.75 (GC); correlations for GC ranged from r = 0.34 (clinician-
rated composite) to r = 0.74 (EF). Findings were similar when depressive symptoms were 
controlled in the analysis, as shown in Table 3b. When data were analyzed by staging groups 
(Table 3c), EF was significantly correlated with all measures except objective and clinician-
rated composites for late-stage HD. GC was significantly correlated with all measures except 
objective composite for prodromal and late-stage and clinician-rated composite for late-
stage. The prodromal group had larger magnitudes of correlations between GC and EF with 
other scores than the late-stage group. EF and GC had the largest correlation coefficients 
with the objective composite in the early-stage group though the correlations were 
considered weak, 0.20 and 0.19 for EF and GC, respectively. It was noted that GC was 
moderately correlated with PROMIS Depression across groups. Depression scores were 48.9 
(SD=9.3), 51.0 (SD=10.9) and 51.2 (SD=10.9) for prodromal, early-stage and late-stage 
groups, respectively.
Table 4 and Figure 1 provide support for known-groups validity. As hypothesized, 
individuals with late-stage HD consistently self-reported worse cognition than the other two 
groups, and their scores were about 1 SD below the normative population mean. These 
findings indicated the late-stage HD group had significantly (p<0.001) poorer self-reported 
cognition than the other two groups. Large effect sizes (η2 ≥ 0.16) were found on all but GC, 
in which a moderate effect size was found (η2 =0.10). Similar conclusions were found when 
analyses controlled for depressive symptoms (not shown in Table 4).
ROC results showed that the Neuro-QoL EF demonstrated high sensitivity (85.2%) and 
moderate specificity (55.4%), with an AUC of 0.79 and likelihood ratio of 5.76 for 
distinguishing prodromal HD versus manifest HD (see Figure 2a). Logistic regression results 
showed an accurate classification rate of 73.2%. Neuro-QoL GC demonstrated high 
sensitivity (86.2%) and poor specificity (30.9%), with an AUC of 0.68 and a likelihood ratio 
of 6.25 for distinguishing prodromal HD versus manifest HD (Figure 2b). The accurate 
classification rate was 64%.
Neuro-QoL EF demonstrated moderate sensitivity (72.8%) and moderate specificity 
(62.3%), with an AUC of 0.75 and a likelihood ratio of 2.68 for distinguishing those with 
and without clinical impairment (239 participants classified as impaired) (Figure 2c); 
findings met our a priori criteria for clinical decision making. The accurate classification rate 
was 67.8%. Neuro-QoL GC demonstrated high sensitivity (75.7%) and poor specificity 
(56.4%), with an AUC of 0.69 and a likelihood ratio of 3.12 for distinguishing prodromal 
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HD versus manifest HD (Figure 2d); again, findings met our a priori criteria for clinical 
decision making. The accurate classification rate was 66.7%.
DISCUSSION
This study provides evidence to support the reliability and validity of the Neuro-QoL GC 
and EF in individuals with HD, as at least 75% of the results were in accordance with the 
hypotheses. [54] Floor and ceiling effects of these measures met a priori criterion, however, 
they were less discriminative at the higher functioning levels. In addition, both measures 
demonstrated significant correlations with neuropsychological tests and clinician-related 
cognition for individuals with prodromal and early-stage HD; convergent validity was 
supported by significant correlations among the self-report measures, and less robust 
correlations among self-report and clinician-rated measures supported discriminant validity. 
Criterion validity was generally supported by analyses that examined sensitivity and 
specificity. Specifically, Neuro-QoL EF and GC both met criterion for clinical decision 
making with regard to being able to differentiate between those with and without manifest 
HD as well as to differentiate between those with and without manifest HD clinical 
impairment. Known-groups validity was supported in that individuals with prodromal HD 
reported better overall cognition than either of the manifest HD groups, and those with 
early-HD reported better cognition than those with later-stage HD. In addition, these 
declines in self-report scores across groups tracked with the objective and clinician-rated 
declines across groups. The fact that EF and GC significantly discriminated among the 
different groups with moderate (GC) or large (EF) effect sizes suggests that monitoring 
Neuro-QoL GC and EF scores, along with other tests, in routine follow-up care has the 
potential to identify those with deteriorating cognition so they can be provided with timely 
remediation/intervention.
Unlike neuropsychological tests which assess cognition in a controlled environment using 
structured procedures, the Neuro-QoL GC and EF are designed to capture participant 
perception of their cognitive decrements and the impact of cognitive decrements on daily 
activities, respectively. Though GC and EF were highly correlated, we noted that strengths 
of correlations with other measures varied. As shown in Table 3a, compared to GC, EF 
showed a trend of having larger magnitudes of correlations with objective and clinician-rated 
cognitive measures, while GC showed a trend of having a larger magnitudes of correlations 
with depression than EF did and this relationship was consistently moderate regardless of 
HD stage. We speculated that this was because most EF items consisted of “concrete” tasks 
(e.g., “remembering where things were placed or put away (e.g., keys)?”), allowing 
individuals to respond to these items using their own experiences, while participants might 
need to provide their subjective impressions of their functioning to respond to “abstract” GC 
questions (e.g., “I had trouble thinking clearly”). The fact that significant correlations of GC 
with other cognitive measures remained when controlling for depression indicated GC might 
tap both depression and cognition. Thus, we speculated that the Neuro-QoL EF and GC 
measured cognition and depressive symptoms simultaneously to some extent, in which EF 
tapped more cognition than depression while GC tapped more depression than cognition. 
Future studies should be done to test this hypothesis.
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It was also noted that the strength of their relationship with cognition decreased along with 
the worsening stage and the relationship between GC and depression remained similar. 
Additionally, as shown in Table 3c, the fact that the magnitude of correlation coefficients 
between EF and GC with clinician-rated and objective composites decreased when disease 
stage got worse suggests that individuals with more advanced stage HD might have more 
anosognosia due to their worsening cognitive functioning. We thus recommend clinician-
rated cognition may provide a more reliable assessment of cognition than self-reported 
cognition for patients with late-stage HD. Our finding in this study and other work in HD 
[55] warrant further studies to evaluate whether the same findings can be replicated by using 
a different sample group.
There are advantages of implementing the validated Neuro-QoL GC and EF in clinical 
practice. The Neuro-QoL was developed via rigorous qualitative and quantitative approaches 
and can be administered via static short-forms or computerized adaptive testing (CAT), and 
scores obtained from both short-forms and CAT are comparable to the scores obtained from 
the full-length item banks. [56; 57] The promise that CAT testing holds for clinical 
monitoring has been documented in the literature, [56–58] and meets the clinical needs of 
individuals with HD. Using this approach, a precise estimate of GC and EF can be obtained 
with the presentation of only a few items with a short period of time, in this study population 
within one minute; such brevity is well-suited for individuals with HD. Because of the 
progressive nature of HD, longitudinal studies of cognition are common, and measures that 
can briefly and sensitively assess cognition can help patient and families understand their 
current status and make adjustments in their daily living.
We acknowledge several study limitations. First, this study utilized a convenience sample 
that targeted individuals who were recruited through other research studies and through 
large, established HD clinics and may not represent the HD population at large. This sample 
was primarily Caucasian, and therefore, generalizability to other racial/ethnic groups is 
uncertain. Furthermore, the majority of our sample had greater than a high school education. 
While findings may not be as generalizable for those with high school or less education, 
analyses that focused on clinical impairment utilized an objective cognitive test that 
corrected for age and education (somewhat mitigating these concerns). Also, more research 
is needed to establish test-retest reliability and responsiveness to change of the Neuro-QoL 
cognition measures in HD.
In conclusion, GC and EF as measured by using the Neuro-QoL measurement system were 
significantly correlated with objective (neuropsychological testing) and clinician-rated 
cognition in prodromal and early-stage HD. Both Neuro-QoL EF and GC demonstrated high 
sensitivity in distinguishing cognition reported by individuals with prodromal HD versus 
manifest HD. We suggest Neuro-QoL EF and GC can be used as complementary sources to 
objective- and clinician-rated cognition to monitor cognition of patients with prodromal and 
early-stage HD. The Neuro-QoL measures are ready to be used in research settings and are 
available in HealthMeasures, http://www.healthmeasures.net.
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Figure 1. 
Comparisons of EF, GC, neuropsychological tests, and three composite scores across HD 
groups (prodromal, early- and late-stage HD)
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Figure 2. 
Receiver operating characteristic (ROC) of Neuro-QoL Executive Function (EF) and 
General Concern (GC)
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